Table of contents
- Brexit
- Updated MHRA guidance—two-year notice period to amend recognition of EU batch testing
- Amending Regulation on derogation from wholesalers’ obligation to decommission unique identifier of products exported to UK published in Official Journal
- Coronavirus (COVID-19)
- Gove outlines plans to review coronavirus (COVID-19) status certificates
- Coronavirus (COVID-19)—European Commission proposes a Digital Green Certificate
- MHRA responds to Ireland’s suspension of AstraZeneca coronavirus (COVID-19) vaccine
- MHRA response to AstraZeneca coronavirus (COVID-19) vaccine suspension
- EMA investigation into coronavirus (COVID-19) AstraZeneca vaccination update
- Commission publishes guidance on standards for coronavirus (COVID-19) rapid tests
More sections of this document available when you sign-in to Lexis+ or register for a free trial.
Article summary
This week's edition of Life Sciences weekly highlights includes news that the MHRA has introduced a two-year notice period for any changes to the continued recognition of EU batch testing, updates on the UK and EU plans to introduce coronavirus (COVID-19) vaccine certificates, the revised go-live date for the EU IT systems required by Regulation (EU) 536/2014, the Clinical Trials Regulation, to 31 January 2022, and the Medical Device Co-ordination Group’s Q&A guidance on custom-made medical devices.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial